U.S. Markets open in 2 hrs 11 mins
S&P Futures
2,443.75
+2.25 (+0.09%)Dow Futures
21,824.00
+29.00 (+0.13%)
| Previous Close | 4,495.00 |
| Open | 4,494.50 |
| Bid | 4,519.00 x 6100 |
| Ask | 4,519.50 x 13000 |
| Day's Range | 4,491.50 - 4,527.50 |
| 52 Week Range | 3,996.00 - 5,520.00 |
| Volume | 377,673 |
| Avg. Volume | 2,120,084 |
| Market Cap | 57.21B |
| Beta | 0.62 |
| PE Ratio (TTM) | 16.93 |
| EPS (TTM) | 267 |
| Earnings Date | Nov 9, 2017 |
| Dividend & Yield | 2.79 (4.97%) |
| Ex-Dividend Date | 2017-08-10 |
| 1y Target Est | 62.35 |
- The Wall Street Journal•2 days ago
[$$] German Biotech Startup Ethris Strikes Respiratory Drug Deal With AstraZeneca
AstraZeneca PLC is betting that technology from German startup Ethris GmbH will help it add to its stockpile of treatments for respiratory diseases.
- MarketWatch•3 days ago
Champions Oncology shares surge 8% on news of AstraZeneca collaboration
Champions Oncology Inc. shares surged 8.2% in premarket trade Monday on news of the company's collaboration with AstraZeneca . The companies plan to develop new Patient-Derived Xenograft (PDX) models -- ...
- Barrons.com•6 days ago
Tesaro: Losing Its Edge?
The FDA decided yesterday to expand the use of the ovarian cancer drug Lynparza, sold by AstraZeneca (AZN) and Merck (MRK). The two drugs belong to a class known as PARP inhibitors. Approved in 2014, AstraZeneca's Lynparza was the first such drug to make its way through the FDA.
